Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 18/20 | 0.43 |
| ▸ | DRD2 | P14416 | 5/20 | 0.43 |
| ▸ | HTR2A | P28223 | 5/20 | 0.43 |
| ▸ | HTR1A | P08908 | 5/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | HTR1B | P28222 | 9/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6808728 | 0.89 | HTR1D (0.45) | HTR1DDRD2HTR2AHTR1ADRD4 | |
| SCHEMBL20921241 | 0.85 | HTR1D (0.41) | HTR1DDRD2HTR2AHTR1ADRD4 | |
| SCHEMBL20921215 | 0.85 | HTR1D (0.41) | HTR1DDRD2HTR2AHTR1ADRD4 | |
| SCHEMBL8550172 | 0.84 | HTR1D (0.46) | HTR1DDRD2HTR2AHTR1ADRD4 | |
| SCHEMBL8551173 | 0.82 | HTR1D (0.41) | HTR1DDRD2HTR2AHTR1ADRD4 | |
| SCHEMBL6812048 | 0.81 | HTR1D (0.56) | HTR1DDRD2HTR2AHTR1ADRD4 | |
| SCHEMBL5093578 | 0.81 | HTR1D (0.56) | HTR1DDRD2HTR2AHTR1ADRD4 | |
| SCHEMBL8549578 | 0.80 | HTR1D (0.62) | HTR1DDRD2HTR2AHTR1ADRD4 | |
| SCHEMBL6811442 | 0.76 | HTR1D (0.42) | HTR1DDRD2HTR2AHTR1ADRD4 | |
| SCHEMBL6811669 | 0.76 | HTR1D (0.42) | HTR1DDRD2HTR2AHTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266503-B1 | Sulfoxide ligand metal catalyzed oxidation of olefins | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266503-B1 | Sulfoxide ligand metal catalyzed oxidation of olefins | YAP1, ICOSLG, SPIN3 | HTR1D 840/4885DRD2 813/4885HTR2A 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.